Guided Therapeutics Inc. (GTHP)

Last Closing Price: --

Company Description

GUIDED THERAPEUTICS, Inc. is developing a rapid and painless test for the early detection of disease that leads to cervical cancer. The technology is designed to quickly eliminate false positive Pap and HPV results and discover cervical disease missed by existing tests. Unlike Pap and HPV tests, the device does not require a painful tissue sample and results are available immediately. GT also owns technology for measuring substances in interstitial fluid, a secondary circulatory system in the body that surrounds the cells.

Financials, Fundamental Metrics & Ratios
Revenue (Most Recent Fiscal Year) $0.01M
Net Income (Most Recent Fiscal Year) $-2.42M
PE Ratio (Current Year Earnings Estimate) --
PE Ratio (Trailing 12 Months) --
PEG Ratio (Long Term Growth Estimate) --
Price to Sales Ratio (Trailing 12 Months) --
Price to Book Ratio (Most Recent Quarterly Book Value per Share) --
Price to Cash Ratio (Most Recent Annual Cash Flow per Share) --
Pre-Tax Margin (Trailing 12 Months) -244200.00%
Net Margin (Trailing 12 Months) --
Return on Equity (Trailing 12 Months) --
Return on Assets (Trailing 12 Months) -197.32%
Current Ratio (Most Recent Fiscal Quarter) 0.14
Quick Ratio (Most Recent Fiscal Quarter) 0.03
Debt to Common Equity (Most Recent Fiscal Quarter) --
Inventory Turnover (Trailing 12 Months) 0.00
Book Value per Share (Most Recent Fiscal Quarter) $-0.09
Earnings per Share (Most Recent Fiscal Quarter) --
Earnings per Share (Most Recent Fiscal Year) --
Diluted Earnings per Share (Trailing 12 Months) $-0.05
Stock
Exchange --
Sector --
Industry --
Common Shares Outstanding 78.91M
Free Float 26.17M
Market Capitalization $11.05M
Average Volume (Last 20 Days) 6968.80
Beta (Past 60 Months) 0.21
Percentage Held By Insiders (Latest Annual Proxy Report) 66.83%
Percentage Held By Institutions (Latest 13F Reports) 9.69%
Annual Dividend (Based on Last Quarter) $0.00
Dividend Yield (Based on Last Quarter) 0.00%